Pilot study of Resveratrol in patients with Glaucoma

An open label clinical pilot study of the effect of resveratrol in patients with Glaucoma

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12612000258853

Enrollment

Registered

2012-03-01

Start date

2012-07-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The primary aims of this study are to determine whether the electroretinogram (ERG), particularly the Phototopic negative response (PhNR) can be improved in patients with glaucoma who take oral supplementation with Resveratrol (RSV) of different doses. Participants undertake full-field ERG testing and their recordings of responses are examined to determine whether there is a difference in ERG parameters between glaucoma patients taking different doses of RSV and after a wash-out period after stopping RSV.

Interventions

Dose escalation study where patients with glaucoma are given 1 gram Resveratrol (oral capsule) daily for 2 weeks followed by 5 grams of Resveratrol (oral capsule) daily for 2 weeks.

Study design

Allocation

Non-randomised trial

Intervention model

Single group

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients with ocular hypertension, mild to moderate glaucoma

Exclusion criteria

Advanced glaucoma Pregnancy Severe renal or hepatic impairment Documented allergy to Resveratrol

Outcome results